United Capital Financial Advisers LLC Has $32.26 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

United Capital Financial Advisers LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGNGet Rating) by 0.7% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 133,416 shares of the medical research company’s stock after acquiring an additional 987 shares during the period. United Capital Financial Advisers LLC’s holdings in Amgen were worth $32,263,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of AMGN. Rational Advisors LLC acquired a new stake in Amgen during the first quarter worth about $26,000. Landmark Wealth Management LLC acquired a new stake in Amgen during the first quarter worth about $28,000. CKW Financial Group acquired a new stake in Amgen during the first quarter worth about $31,000. Baltimore Washington Financial Advisors Inc. bought a new position in shares of Amgen in the fourth quarter worth about $33,000. Finally, Joseph Group Capital Management bought a new position in shares of Amgen in the fourth quarter worth about $34,000. 77.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of research reports. TheStreet raised shares of Amgen from a “c+” rating to a “b” rating in a report on Monday, August 15th. Piper Sandler increased their target price on shares of Amgen from $260.00 to $265.00 and gave the stock an “overweight” rating in a report on Friday, August 5th. Morgan Stanley increased their target price on shares of Amgen from $239.00 to $253.00 and gave the stock an “equal weight” rating in a report on Friday, July 15th. StockNews.com cut shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Monday, August 8th. Finally, Atlantic Securities dropped their target price on shares of Amgen from $190.00 to $182.00 and set an “underweight” rating for the company in a report on Tuesday, August 9th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Amgen presently has an average rating of “Hold” and an average target price of $245.14.

Insiders Place Their Bets

In other Amgen news, Director R Sanders Williams sold 200 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $249.96, for a total transaction of $49,992.00. Following the completion of the transaction, the director now owns 5,301 shares in the company, valued at approximately $1,325,037.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director R Sanders Williams sold 200 shares of the firm’s stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $249.96, for a total transaction of $49,992.00. Following the completion of the sale, the director now owns 5,301 shares of the company’s stock, valued at approximately $1,325,037.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Robert Eckert sold 6,600 shares of the firm’s stock in a transaction that occurred on Thursday, August 18th. The stock was sold at an average price of $249.00, for a total transaction of $1,643,400.00. Following the sale, the director now directly owns 21,184 shares of the company’s stock, valued at approximately $5,274,816. The disclosure for this sale can be found here. Company insiders own 0.46% of the company’s stock.

Amgen Stock Up 0.9 %

Shares of NASDAQ AMGN opened at $247.69 on Friday. The company has a debt-to-equity ratio of 14.76, a current ratio of 1.53 and a quick ratio of 1.17. Amgen Inc. has a 1 year low of $198.64 and a 1 year high of $258.45. The company has a 50 day simple moving average of $246.58 and a 200 day simple moving average of $243.40. The firm has a market cap of $132.50 billion, a PE ratio of 20.99, a price-to-earnings-growth ratio of 1.98 and a beta of 0.56.

Amgen (NASDAQ:AMGNGet Rating) last released its quarterly earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.25. Amgen had a net margin of 24.92% and a return on equity of 218.34%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.53 billion. During the same quarter last year, the business earned $4.38 EPS. The company’s revenue was up 1.0% compared to the same quarter last year. On average, research analysts forecast that Amgen Inc. will post 17.45 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Thursday, August 18th were issued a dividend of $1.94 per share. The ex-dividend date was Wednesday, August 17th. This represents a $7.76 annualized dividend and a yield of 3.13%. Amgen’s payout ratio is 65.76%.

Amgen Company Profile

(Get Rating)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

Further Reading

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.